JP2021517457A5 - - Google Patents

Download PDF

Info

Publication number
JP2021517457A5
JP2021517457A5 JP2020548645A JP2020548645A JP2021517457A5 JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5 JP 2020548645 A JP2020548645 A JP 2020548645A JP 2020548645 A JP2020548645 A JP 2020548645A JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548645A
Other languages
English (en)
Japanese (ja)
Other versions
JP7209008B2 (ja
JP2021517457A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/056197 external-priority patent/WO2019175198A2/en
Publication of JP2021517457A publication Critical patent/JP2021517457A/ja
Publication of JP2021517457A5 publication Critical patent/JP2021517457A5/ja
Priority to JP2022143428A priority Critical patent/JP7447208B2/ja
Application granted granted Critical
Publication of JP7209008B2 publication Critical patent/JP7209008B2/ja
Priority to JP2024027970A priority patent/JP7791229B2/ja
Priority to JP2025245068A priority patent/JP2026041981A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548645A 2018-03-12 2019-03-12 抗体 Active JP7209008B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022143428A JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18161293 2018-03-12
EP18161293.8 2018-03-12
EP18175347 2018-05-31
EP18175347.6 2018-05-31
PCT/EP2019/056197 WO2019175198A2 (en) 2018-03-12 2019-03-12 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143428A Division JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体

Publications (3)

Publication Number Publication Date
JP2021517457A JP2021517457A (ja) 2021-07-26
JP2021517457A5 true JP2021517457A5 (https=) 2021-10-07
JP7209008B2 JP7209008B2 (ja) 2023-01-19

Family

ID=65729373

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020548645A Active JP7209008B2 (ja) 2018-03-12 2019-03-12 抗体
JP2022143428A Active JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A Active JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A Pending JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022143428A Active JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A Active JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A Pending JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Country Status (20)

Country Link
US (5) US20200277397A1 (https=)
EP (1) EP3765493A2 (https=)
JP (4) JP7209008B2 (https=)
KR (1) KR20200130723A (https=)
CN (2) CN120795158A (https=)
AU (2) AU2019233523B2 (https=)
BR (1) BR112020018490A2 (https=)
CA (1) CA3093745A1 (https=)
CL (1) CL2020002326A1 (https=)
CO (1) CO2020012524A2 (https=)
CR (3) CR20200463A (https=)
EC (1) ECSP20063690A (https=)
IL (1) IL277030A (https=)
MA (1) MA52152A (https=)
MX (7) MX2020009379A (https=)
PE (1) PE20210339A1 (https=)
PH (1) PH12020551447A1 (https=)
SA (3) SA523440623B1 (https=)
SG (1) SG11202008399QA (https=)
WO (1) WO2019175198A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
EP4028424A1 (en) * 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
WO2022056354A1 (en) * 2020-09-11 2022-03-17 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
CA3217716A1 (en) * 2021-05-04 2022-11-10 Oren Bogin Anti-5t4 antibodies and uses thereof
WO2023107954A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
CN119546329A (zh) 2022-04-11 2025-02-28 瑞泽恩制药公司 用于通用肿瘤细胞杀伤的组合物和方法
JP2025537193A (ja) * 2022-11-08 2025-11-14 フェインズ セラピューティクス，インコーポレーテッド 抗５ｔ４抗体及びその使用
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
EP1717248A1 (en) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
PE20100251A1 (es) 2004-09-10 2010-04-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
MY148763A (en) 2006-03-10 2013-05-31 Wyeth Corp Anti-5t4 antibodies and uses thereof
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
MX2014003313A (es) * 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
WO2014137931A1 (en) 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
MX373245B (es) 2013-07-05 2020-05-11 Genmab As Anticuerpos cd3 humanizados o quiméricos.
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
US10941207B2 (en) * 2014-12-19 2021-03-09 Chiome Bioscience, Inc Fusion protein comprising three binding domains to 5T4 and CD3
CN108368172B (zh) 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
CN113862300A (zh) 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
BR112018010394A8 (pt) * 2015-11-24 2019-02-26 Synthon Biopharmaceuticals Bv anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo.
CN110698560B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
AU2017252233A1 (en) * 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
CN108285487B (zh) 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
US11608384B2 (en) 2017-04-05 2023-03-21 Xdcexplorer (Shanghai) Co., Ltd. Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications
SG11202000503QA (en) 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
EP4028424A1 (en) * 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer

Similar Documents

Publication Publication Date Title
JP2021517457A5 (https=)
US20210169936A1 (en) Cryopreserved NK cells preloaded with an antibody construct
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
EP3882276A1 (en) Bispecific antibody, preparation method therefor and application thereof
NZ791623A (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2018531219A6 (ja) Ｐｄ−ｌ１抗体
JP2018531219A (ja) Ｐｄ−ｌ１抗体
WO2020114479A1 (zh) 多特异性蛋白分子
CN114981301B (zh) Pd1和vegfr2双结合剂
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
CN112166125B (zh) 全人源的抗lag-3抗体及其应用
CN112771075A (zh) 结合至cd33和cd3的双特异性抗体构建体的延长施用
US20230312709A1 (en) Antibody targeting CD47 and application thereof
CN119060184B (zh) 抗rage抗体及其应用
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4703384A1 (en) Bispecific antibody targeting g protein-coupled receptor
US20240376208A1 (en) Duplexbodies
CN115368457A (zh) 抗tigit抗体及其用途
Zettlitz et al. Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70)
JP2022547135A (ja) 増強されたプロテインｌ捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
CN119371542B (zh) 抗rage抗体及其应用
JP7844430B2 (ja) 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体
US20240376196A1 (en) Cd112 antibody and use
WO2024088386A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof